NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
- Since the interim results were released in March, patient enrollment has nearly doubled
- Of the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screening
- Nearly 90% of patients that completed the Phase 2a trial to date have rolled over into the open label extension (OLE) study
- Patients in the OLE study (both NT1 and NT2) remain on Quilience monotherapy, without any additional stimulant, wake promoting nor anti-cataplectic treatment, with several on therapy for over 5 months
ZURICH, SWITZERLAND / ACCESSWIRE / May 4, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that 90% of the 60 patients required to complete its Phase 2a clinical trial for Quilience (Mazindol ER) have been randomized and the Company continues to expect to report final results from this ground-breaking trial by mid-Q3 2022.
Read entire article here: https://www.accesswire.com/700091/NLS-Pharmaceutics-Achieves-90-Enrollment-Milestone-in-QuilienceR-Phase-2a-Clinical-Trial-for-Patients-with-Narcolepsy
